Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

Anti-IL-6 A breakthrough active immunotherapy for the treatment of osteoarthritis

Coordinator
Peptinov, France
Runs
1 March 2024 to 28 February 2026
Status
Running
EU funding
€2.5m
Total cost
€4.0m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101145362

What the project is doing

In the project's own words, from its summary on CORDIS.

Osteoarthritis is a debilitating disease affecting the joint and a leading cause of disability worldwide. It affects at least 250m people and incurs healthcare costs of toward 0.5% of the GDP. Peptinov is developing an active immunotherapy that can halt inflammation-driven destruction of the cartilage in the joints. We use a unique approach to neutralise a key pro-inflammatory protein (IL-6) driving chronic inflammation.

Our vaccine-like approach stimulates the patients own immune system to produce antibodies against excess IL-6 and neutralise its biological function. By doing so we will halt disease progression. Our treatment will cost 5-10% of conventional immunotherapies as we inject patients with inexpensive, immunogenic peptides to stimulate production of endogenous antibodies. Phase I clinical trial yielded very encouraging preliminary safety and tolerability data on 24 patients.

This project will implement the Phase II clinical trial and make our therapy out-licensing ready.

Topics

Who is involved

OrganisationCityCountryRole
PeptinovParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI